<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379365</url>
  </required_header>
  <id_info>
    <org_study_id>MS-4500</org_study_id>
    <secondary_id>MS-4500</secondary_id>
    <nct_id>NCT01379365</nct_id>
  </id_info>
  <brief_title>Cryo-Touch III Refinement Study Investigational Plan</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>MyoScience, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MyoScience, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized study to evaluate the performance of the MyoScience
      Cryo-Touch III device for the treatment of glabellar and/or forehead wrinkles.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wrinkle Severity and incidence of device-related serious adverse events</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Effectiveness endpoint: Wrinkle severity in the target area in animation at 30 days post-treatment as rated by the investigator using the 5-point grading scale.
Safety endpoint: Incidence of device-related serious adverse events (DSAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wrinkle Severity</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>• Investigators' rating of wrinkle severity in the target area in animation immediately post-treatment, at 1 and 7 days post-treatment and at 30-day intervals for 120 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independent Assessment</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>• Independent reviewers' ratings of forehead wrinkle severity at rest and in animation at 30-days post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>• Subjects' global assessment of change in appearance of target area immediately post-treatment, at 1 and 7 days post-treatment and at 30-day intervals for 120 days after treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Facial Wrinkles</condition>
  <condition>Skin Aging</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryo-Touch III</intervention_name>
    <description>Percutaneous treatment with the device</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30-70 years

          -  Subject has a glabellar and/or forehead wrinkle rating by investigator of at least 2
             in animation on the 5-point Wrinkle Scale (5WS)*

          -  Subject has signed institutional review board (IRB)-approved informed consent form

        Exclusion Criteria:

          -  Subject takes any medication or dietary supplement regularly that affects blood
             clotting (e.g., Coumadin, aspirin, clopidogrel) or increases the risk of
             bleeding/bruising

          -  Subject has had prior surgery that alters the subcutaneous anatomy of the target
             treatment sites

          -  The investigator is unable to substantially lessen facial lines by physical separation

          -  Subject has undergone another facial cosmetic procedures at or above the level of the
             cheekbones within the past 6 months

          -  Subject is participating in another facial cosmetic research study

        Patient has any of following conditions:

          -  History of facial nerve palsy

          -  Marked facial asymmetry

          -  Ptosis

          -  Excessive dermatochalasis

          -  Deep dermal scarring

          -  Thick sebaceous skin

          -  History of neuromuscular disorder

          -  Chronic dry eye symptoms

          -  Allergy or intolerance to lidocaine

          -  Other local skin condition (eg, skin infection) at target treatment site

          -  Any physical or psychiatric condition that in the investigator's opinion would prevent
             adequate study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Aesthetics Research Center</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wrinkle rhytid aging</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

